Home/Filings/4/0001213900-25-082904
4//SEC Filing

Papapetropoulos Spyros 4

Accession 0001213900-25-082904

CIK 0001191070other

Filed

Sep 1, 8:00 PM ET

Accepted

Sep 2, 7:02 AM ET

Size

5.8 KB

Accession

0001213900-25-082904

Insider Transaction Report

Form 4
Period: 2025-08-27
Papapetropoulos Spyros
DirectorPresident and CEO
Transactions
  • Award

    Employee Stock Option (Right-to- Buy)

    2025-08-27$8.27/sh+34,559$285,80374,088 total
    Exercise: $8.27Exp: 2035-08-27Common Stock (34,559 underlying)
Footnotes (1)
  • [F1]Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested.

Documents

1 file

Issuer

Neuphoria Therapeutics Inc.

CIK 0001191070

Entity typeother

Related Parties

1
  • filerCIK 0001832694

Filing Metadata

Form type
4
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 7:02 AM ET
Size
5.8 KB